Cases & Deals

GE Healthcare acquires Rapidscan

Clients General Electric Company

Jones Day advised GE Healthcare in connection with its acquisition of Rapidscan Pharma Solutions, Inc., which is a single product pharmaceutical company with the exclusive rights to produce and sell the pharmacological stress agent Rapiscan® (regadenoson) in territories outside of North America.  Rapiscan® is a European Medicines Agency (EMA) approved selective coronary vasodilator, used as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients. It is used in the diagnosis of coronary artery disease (CAD), the most common type of cardiovascular disease.